Table 2 from Camizestrant in Combination with Three Globally Approved CDK4/6 Inhibitors in Women with ER+, HER2− Advanced Breast Cancer: Results from SERENA-1

Richard D. Baird; Begoña Bermejo; Manuel Ruíz-Borrego; Christos Vaklavas; Irene Moreno; Mafalda Oliveira; Anne Armstrong; Nicholas C. Turner; Jason Incorvati; Chris Twelves; Eva Ciruelos; Erika Hamilton; Manish R. Patel; Peter Kabos; Carmela Ciardullo; Teresa Klinowska; Justin P.O. Lindemann; Alastair Mathewson; Christopher J. Morrow; Andy Sykes; Jincheng Yang; Bairu Zhang; Iván Victoria

doi:10.1158/1078-0432.30363312

Key Points

Adverse effects in over 20% of patients combined camizestrant with CDK4/6 inhibitors.
The study involves women with ER+, HER2− advanced breast cancer receiving treatment.
Analysis of adverse outcomes utilized data from SERENA-1 trial, focusing on AE profiles.
Highlights importance of understanding adverse effects for better therapeutic strategies.

Implication

Results reveal adverse effects of camizestrant with CDK4/6 inhibitors in women with ER+, HER2− advanced breast cancer, suggesting guidance for treatment strategies.

Abstract

AE profile for camizestrant in combination with abemaciclib, palbociclib, or ribociclib (irrespective of causality); AEs reported in ≥20% of patients.a

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Baird et al. (2025) studied this question.

synapsesocial.com/papers/68f199bfde32064e504dcc36 https://doi.org/10.1158/1078-0432.30363312

View Full Paper

Ask AI

Bookmark

Share

Table 2 from Camizestrant in Combination with Three Globally Approved CDK4/6 Inhibitors in Women with ER+, HER2− Advanced Breast Cancer: Results from SERENA-1

Key Points

Implication

Abstract

Discussion

Cite This Study

Table 2 from Camizestrant in Combination with Three Globally Approved CDK4/6 Inhibitors in Women with ER+, HER2− Advanced Breast Cancer: Results from SERENA-1

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

More related papers

Keep reading

More related papers